White Paper
Understanding GLP-1 Agonists: The ‘Weight Loss’ Drugs Taking the World by Storm
White Paper Summary
What were once drugs intended for type 2 diabetes, GLP-1 agonists have exploded in popularity due to their secondary function to help lose weight. However, while there are currently 10 GLP-1 agonist drugs on the market, only three of these are FDA approved for the treatment of obesity.
“The weight loss benefits of GLP-1 seem to be what’s driving popularity,” said Kelly Riedl, PA-C, CPHRM, Senior Risk Management Consultant, ProAssurance. “However, because of that popularity we’ve seen supply not being able to keep up with demand, leading to drug shortages.”
Shortages further drive off-label prescribing and have led patients to seek alternative sources, through the web or from compounding pharmacies.
Off-label use of drugs, such as those that are compounded, can play an important role for patients. But it’s important to also note that compounded GLP-1 drugs are not
FDA approved, and thus have not undergone the same testing for safety or quality.
Prescribers and patients alike must better understand the environment surrounding GLP-1 drugs so that they can further increase patient safety and decrease potential liability.
To learn more about ProAssurance, please visit their website.